Ligand Targretin gel
Executive Summary
Topical bexarotene 1% formulation approved June 28 for treatment of cutaneous lesions in patients with early-stage cutaneous T-cell lymphoma who have refractory or persistent disease after other therapies or have not tolerated other therapies. Targretin capsules were approved Dec. 29 as a second-line CTCL treatment (1"The Pink Sheet" Jan. 10, p. 3)